• Fennec Pharmaceuticals flagged rising clinical interest in PEDMARK, with four study abstracts accepted for 2026 ASCO Annual Meeting, May 29-June 2 in Chicago.
• Results have not yet been presented; full abstracts are scheduled to post May 21, 2026, with two studies set for poster presentation May 31 and June 1.
• Studies span pediatric, young adult, and adult settings, assessing sodium thiosulfate use alongside cisplatin to help prevent treatment-related hearing loss.
• Focus includes real-world feasibility and tolerability, audiometric outcomes, delayed dosing in pediatric patients, and a randomized Phase 1 program in metastatic germ cell tumor.
• Update supports PEDMARK expansion narrative beyond its current US pediatric label, with potential to broaden clinical adoption if data reinforce benefit without undermining cancer treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fennec Pharmaceuticals Inc. published the original content used to generate this news brief on May 07, 2026, and is solely responsible for the information contained therein.